These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26822362)

  • 41. Use and abuse of tissue culture in neurotoxicity studies: overview of the session.
    Verity MA
    Neurotoxicology; 1991; 12(3):457-8. PubMed ID: 1684033
    [No Abstract]   [Full Text] [Related]  

  • 42. Themed series on neuropharmacology.
    Fundam Clin Pharmacol; 2021 Jun; 35(3):500. PubMed ID: 34013524
    [No Abstract]   [Full Text] [Related]  

  • 43. Editorial: New Paradigms in Neuroscience and Related Targets for Drug Discovery.
    Salomone S
    Front Pharmacol; 2020; 11():750. PubMed ID: 32499713
    [No Abstract]   [Full Text] [Related]  

  • 44. Novel drug targeting and delivery techniques: Avenues for the advancement of neuropharmacology.
    Sitta R
    Brain Circ; 2018; 4(2):79-80. PubMed ID: 30276342
    [No Abstract]   [Full Text] [Related]  

  • 45. Pump the brakes: identifying neurobiological targets to enhance inhibitory control in drug addiction.
    Ceceli AO; Goldstein RZ
    Neuropsychopharmacology; 2024 Jul; ():. PubMed ID: 39020140
    [No Abstract]   [Full Text] [Related]  

  • 46. New vistas in drug abuse research.
    Leshner AI
    CNS Spectr; 2000 May; 5(5):19. PubMed ID: 18268463
    [No Abstract]   [Full Text] [Related]  

  • 47. The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice.
    Lopez MF; Moorman DE; Aston-Jones G; Becker HC
    Brain Res; 2016 Apr; 1636():74-80. PubMed ID: 26851547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological blockage of NOP receptors decreases ventral tegmental area dopamine neuronal activity through GABA
    Petrella M; Borruto AM; Curti L; Domi A; Domi E; Xu L; Barbier E; Ilari A; Heilig M; Weiss F; Mannaioni G; Masi A; Ciccocioppo R
    Neuropharmacology; 2024 May; 248():109866. PubMed ID: 38364970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Crosstalk between the Cannabinoid Receptors and Nociceptin Receptors in Colitis-Clinical Implications.
    Wołyniak M; Małecka-Wojciesko E; Zielińska M; Fabisiak A
    J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A mechanistic overview of approaches for the treatment of psychostimulant dependence.
    Jensen KL; Jensen SB; Madsen KL
    Front Pharmacol; 2022; 13():854176. PubMed ID: 36160447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A first-in-human study of
    Kubota M; Seki C; Kimura Y; Takahata K; Shimada H; Takado Y; Matsuoka K; Tagai K; Sano Y; Yamamoto Y; Okada M; Kikuchi T; Ichise M; Kawamura K; Zhang MR; Higuchi M
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2846-2855. PubMed ID: 33566152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetically selected alcohol-preferring msP rats to study alcohol use disorder: Anything lost in translation?
    Borruto AM; Stopponi S; Li H; Weiss F; Roberto M; Ciccocioppo R
    Neuropharmacology; 2021 Mar; 186():108446. PubMed ID: 33476639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future.
    Cannella N; Ubaldi M; Masi A; Bramucci M; Roberto M; Bifone A; Ciccocioppo R
    Neurosci Biobehav Rev; 2019 Aug; 103():384-398. PubMed ID: 31112713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pain And Opioid Systems, Implications In The Opioid Epidemic.
    Massaly N; Morón JA
    Curr Opin Behav Sci; 2019 Apr; 26():69-74. PubMed ID: 30984806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maternal Cigarette Smoke Exposure Worsens Neurological Outcomes in Adolescent Offspring with Hypoxic-Ischemic Injury.
    Chan YL; Saad S; Machaalani R; Oliver BG; Vissel B; Pollock C; Jones NM; Chen H
    Front Mol Neurosci; 2017; 10():306. PubMed ID: 29018327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics.
    Ubaldi M; Cannella N; Ciccocioppo R
    Prog Brain Res; 2016; 224():251-84. PubMed ID: 26822362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurobiological mechanisms in the transition from drug use to drug dependence.
    Koob GF; Ahmed SH; Boutrel B; Chen SA; Kenny PJ; Markou A; O'Dell LE; Parsons LH; Sanna PP
    Neurosci Biobehav Rev; 2004 Jan; 27(8):739-49. PubMed ID: 15019424
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reinforcement principles for addiction medicine; from recreational drug use to psychiatric disorder.
    Edwards S
    Prog Brain Res; 2016; 223():63-76. PubMed ID: 26806771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Translational approach to develop novel medications on alcohol addiction: focus on neuropeptides.
    Ubaldi M; Bifone A; Ciccocioppo R
    Curr Opin Neurobiol; 2013 Aug; 23(4):684-91. PubMed ID: 23648086
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of the neuropeptide S system in addiction: focus on its interaction with the CRF and hypocretin/orexin neurotransmission.
    Cannella N; Kallupi M; Ruggeri B; Ciccocioppo R; Ubaldi M
    Prog Neurobiol; 2013 Jan; 100():48-59. PubMed ID: 23041581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.